Recombinant HIV and modified packaging cells and method for usin

Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424 931, 514 44, 435440, 435455, A61K 4800, C12N 1500, C12N 1585

Patent

active

060633743

ABSTRACT:
A recombinant human immunodeficiency virus (rHIV) and recombinant mammalian cell-line (packaging systems) and a method for treating infection of cells by human immuneodeficiency virus HIV. rHIV, such as rHIV-1, comprises of a gene construction which includes a foreign gene. The expression of this gene is activated in human cells in the presence of wild-type HIV. This gene product can cause cell death in the presence of an appropriate drug, e.g. Acyclovir. This gene product is typically a viral thymidine kinase. rHIV is so constructed that it is unable to replicate by itself due to the absence of a regulatory gene that is necessary for its replication, such as tat or rev or both. The recombinant mammalian cell-line packaging system comprises in its genome a recombinant gene construction which typically includes a functional regulatory gene from HIV which is missing from rHIV, such as the tat or rev genes or both. The method for treating infection of cells by HIV comprises administering a composition comprising rHIV, which is produced in vitro from a recombinant mammalian cell-line, and treating with a nucleoside analog, such as Acyclovir or Gancyclovir.

REFERENCES:
patent: 5149529 (1992-09-01), Ho et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5244792 (1993-09-01), Burke et al.
patent: 5306631 (1994-04-01), Harrison et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5428143 (1995-06-01), Berger et al.
Martin A. Nowak, Andrew J. McMichael "How HIV Defeats the Immune System," Scientific American: Aug. 1995 pp. 58-65.
J. Cohen "Differences in HIV Strains May Underlie Disease Patterns," Science: v.270, Oct. 6, 1995: pp. 30-31.
George W. Nelson and Alan S. Perelson "Modeling Defective Interfering Virus Therapy for AIDS: Conditions for DIV Survival," Mathematical Bioscience, v. 125 (1995): pp. 127-153.
J. Cohen "How Can HIV Replication Be Controlled," Science, v.260, May 28, 1993; p. 1257.
J. Cohen "What Causes Immune System Collapse Seen in AIDS?" Science, v.260, May 28, 1993; p. 1256.
J. Cohen "Can Combination Therapy Overdose Drug Resistance?" Science, v. 260, May 28, 1993: p. 1258.
Lawrence M. Fisher "The Stuff of Dreams Nears Reality" The New York Times, Jun. 1, 1995: C1.
J. Cohen "Can One Type of HIV Protect Against Another Type?" Science, v. 268. Jun. 16, 1995. p. 1566.
Karin Travers, et al. "Natural Protection Against HIV-1 Infection Provided by HIV-2." Science, v. 268. Jun. 16, 1995. p. 1612-1615.
J. Cohen "AIDS Mood Upbeat-For a Change" Science, v.267. Feb. 17, 1995. p. 959.
Rebecca A. Spence et al. "Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors" Science, v. 267. Feb., 17, 1995. p. 988-993.
J. Cohen "High Turnover of HIV in Blood Revealed by New Studies" Science, v. 267. Jan. 13, 1995. p. 179.
William E. Paul "Reexamining AIDS Research Priorities" Science, v. 267. Feb. 3, 1995. p. 633-636.
Mariano A. Garcia-Blanco and Bryan R. Cullen "Molecular Basis of Latency in Pathogenic Human Viruses" Science v.254, Nov. 8, 1991. p. 815-820.
John M. Coffin "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy" Science v.267. Jan. 27, 1995. p. 483-489.
S.L. McKnight and E.R. Grace "Expression of the herpes thymidine kinase gene in Xenopus laevis oocytes: an essay for the study of deletion mutants constructed in vitro" Nucleic Acid.
R. Shibata et al. "Comparative studies on tat mutants of three primate lentiviruses" Acrhice of Virology, v.114. p. 243-250 (1990).
A. Adachi et al. "Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone".
N.J. Deacon et al. "Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients" Science, v.270. Nov. 10, 1995. p.988-991.
Arnold J. Levine Viruses . Scientific American Library, 1992. (Chp 4 and 7).
Dr. W. French Anderson "Gene Therapy for AIDS" Human Gene Therapy, 5:149-150 (1994).
Caruso, M. et al., "HIV-triggered killing of booby trapped cells prevents viral spread in an HIV infected cell population," Bone Marrow Transplant, vol. 9 , suppl. 1, p. 187-188, 1992.
Y. Hasegawa et al., "Retroviral transfer of JSV1-TK gene into human lung cancer cell line," Journal of Molecular Medicine, 73:107-112, (1995).
Orkin et al., NIH Gene Therapy Meeting, Dec. 7, 1995.
Chenciner et al., Res. Virol., 146:171-178, 1995.
Dropulic et al., Human Gene Therapy, 5:927-939, 1994.
Gilboa et al., Trends in Genetics, 10(4):139-144, 1994.
Buchschacher et al., Journal of Virology, 66(5):2731-2739, 1992.
Brady et al., PNAS USA, 91:365-369, 1994.
Marshal, Science 269:1050-1055, 1995.
Miller, FASEB J. 9:190-199, 1995.
Culver, TIG 10(5):174-178, 1990.
Hodgson, Exp. Opin. Ther. Pat 5(5):458-469, 1995.
Harrison, Gail S., et al. "Activation of a Diphtheria Toxin a Gene by Expression of Human Immunodeficiency Virus-1 Tat and Rev Proteins in Transfected Cells." Human Gene Therapy, 2:53-60 (1991).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Recombinant HIV and modified packaging cells and method for usin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant HIV and modified packaging cells and method for usin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant HIV and modified packaging cells and method for usin will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-256291

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.